-
Je něco špatně v tomto záznamu ?
Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis
F. Quhal, K. Mori, R. Sari Motlagh, E. Laukhtina, B. Pradere, M. Rouprêt, A. Necchi, M. Moschini, SF. Shariat,
Jazyk angličtina Země Japonsko
Typ dokumentu srovnávací studie, časopisecké články, metaanalýza, systematický přehled
NLK
ProQuest Central
od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2003-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-03-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-03-01 do Před 1 rokem
- MeSH
- adjuvantní chemoterapie MeSH
- karcinom z přechodných buněk farmakoterapie patologie chirurgie MeSH
- lidé MeSH
- nefroureterektomie MeSH
- neoadjuvantní terapie MeSH
- urologické nádory farmakoterapie patologie chirurgie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- srovnávací studie MeSH
- systematický přehled MeSH
The objectives of this study are to evaluate the available literature regarding the oncologic effect of neoadjuvant and adjuvant chemotherapy in the treatment of patients with clinically non-metastatic upper tract urothelial carcinoma (UTUC) and locally advanced UTUC. We searched PubMed, Cochrane Library, and Scopus databases in November 2019, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We included studies that compared patients with non-metastatic UTUC who received either neoadjuvant or adjuvant chemotherapy with patients who underwent surgery alone. Subgroup meta-analyses were also performed for studies that investigated only locally advanced UTUC. Overall, 36 studies were included in the review of which 22 studies and 15,378 patients were eligible for the meta-analysis. Neoadjuvant chemotherapy (NAC) was associated with higher rates of pathological downstaging (pDS) (RR 6.48, 95% CI 2.05-20.44, p = 0.001) and pathological complete response (RR 18.46, 95% CI 3.34-99.24, p = 0.001); and this was also proven in a subgroup analysis of studies that evaluated pDS in locally advanced UTUC (RR 3.18, 95% CI 2.0-5.07, p < 0.001). The association of NAC with overall survival (OS) and cancer-specific survival (CSS) was also statistically significant in all patients and in patients with locally advanced UTUC. Adjuvant chemotherapy (AC) was associated with improved metastasis-free survival (HR 0.65, 95% CI 0.55-0.76, p < 0.001) and CSS (HR 0.66, 95% CI 0.57-0.77, p < 0.001), which continued to be true for the patients with locally advanced UTUC. The association of AC with OS was only significant in patients with locally advanced UTUC. Perioperative chemotherapy might provide better survival outcomes in patients with clinically non-metastatic UTUC treated with radical nephroureterectomy. Neoadjuvant chemotherapy seems to have promising results, although high level of evidence is still lacking. Despite the low level, the body of evidence suggests a need for multimodal therapy of invasive UTUC.
Department of Urology Luzerner Kantonsspital Luzern Switzerland
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
Sorbonne Université GRC n°5 ONCOTYPE URO AP HP Urology Hôpital Pitié Salpêtrière 75013 Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20024980
- 003
- CZ-PrNML
- 005
- 20201222160045.0
- 007
- ta
- 008
- 201125s2020 ja f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10147-020-01650-9 $2 doi
- 035 __
- $a (PubMed)32206939
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ja
- 100 1_
- $a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
- 245 10
- $a Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis / $c F. Quhal, K. Mori, R. Sari Motlagh, E. Laukhtina, B. Pradere, M. Rouprêt, A. Necchi, M. Moschini, SF. Shariat,
- 520 9_
- $a The objectives of this study are to evaluate the available literature regarding the oncologic effect of neoadjuvant and adjuvant chemotherapy in the treatment of patients with clinically non-metastatic upper tract urothelial carcinoma (UTUC) and locally advanced UTUC. We searched PubMed, Cochrane Library, and Scopus databases in November 2019, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We included studies that compared patients with non-metastatic UTUC who received either neoadjuvant or adjuvant chemotherapy with patients who underwent surgery alone. Subgroup meta-analyses were also performed for studies that investigated only locally advanced UTUC. Overall, 36 studies were included in the review of which 22 studies and 15,378 patients were eligible for the meta-analysis. Neoadjuvant chemotherapy (NAC) was associated with higher rates of pathological downstaging (pDS) (RR 6.48, 95% CI 2.05-20.44, p = 0.001) and pathological complete response (RR 18.46, 95% CI 3.34-99.24, p = 0.001); and this was also proven in a subgroup analysis of studies that evaluated pDS in locally advanced UTUC (RR 3.18, 95% CI 2.0-5.07, p < 0.001). The association of NAC with overall survival (OS) and cancer-specific survival (CSS) was also statistically significant in all patients and in patients with locally advanced UTUC. Adjuvant chemotherapy (AC) was associated with improved metastasis-free survival (HR 0.65, 95% CI 0.55-0.76, p < 0.001) and CSS (HR 0.66, 95% CI 0.57-0.77, p < 0.001), which continued to be true for the patients with locally advanced UTUC. The association of AC with OS was only significant in patients with locally advanced UTUC. Perioperative chemotherapy might provide better survival outcomes in patients with clinically non-metastatic UTUC treated with radical nephroureterectomy. Neoadjuvant chemotherapy seems to have promising results, although high level of evidence is still lacking. Despite the low level, the body of evidence suggests a need for multimodal therapy of invasive UTUC.
- 650 _2
- $a karcinom z přechodných buněk $x farmakoterapie $x patologie $x chirurgie $7 D002295
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a nefroureterektomie $7 D000074682
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a urologické nádory $x farmakoterapie $x patologie $x chirurgie $7 D014571
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
- 700 1_
- $a Sari Motlagh, Reza $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Department of Urology, University Hospital of Tours, Tours, France.
- 700 1_
- $a Rouprêt, Morgan $u Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Urology Hôpital Pitié-Salpêtrière, 75013, Paris, France.
- 700 1_
- $a Necchi, Andrea $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- 700 1_
- $a Moschini, Marco $u Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at. Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at. Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at. Department of Special Surgery, Jordan University Hospital, University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at. European Association of Urology Research Foundation, Arnhem, The Netherlands. shahrokh.shariat@meduniwien.ac.at.
- 773 0_
- $w MED00005747 $t International journal of clinical oncology $x 1437-7772 $g Roč. 25, č. 6 (2020), s. 1037-1054
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32206939 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222160041 $b ABA008
- 999 __
- $a ok $b bmc $g 1599125 $s 1115666
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 25 $c 6 $d 1037-1054 $e 20200323 $i 1437-7772 $m International journal of clinical oncology $n Int J Clin Oncol $x MED00005747
- LZP __
- $a Pubmed-20201125